Activaero appoints chief business officer

Christian Pangratz takes the role

Activaero, a German leader in controlled breathing inhalation technologies and therapeutics, has appointed Christian Pangratz as chief business officer.

Pangratz joins Activaero from Nektar Therapeutics, in San Francisco, US, where he recently served as executive director of business development. He brings to Activaero 20 years of life science experience.

Pangratz will join the Activaero management team and lead all business development, marketing and alliance management activities. He replaces Henrik Luessen, who has decided to focus on his own consultancy firm, but will continue to support Activaero’s business development team on a part-time basis.

You may also like

Finance

Vectura Group to buy Activaero for £108m

Will enable Vectura to build a therapeutic specialist in airways diseases
Manufacturing

Sapio Sciences and Ultima Genomics to work together in advancing multiomics research

The partnership delivers global, end-to-end solutions aimed at making genomics research more streamlined and accessible
Cell & Gene Therapy

Cytiva and WhiteLab Genomics team up to use AI to accelerate cell line development

Collaboration will accelerate stable cell line development in AAV genomic medicine development and ultimately also shorten the development timeline to clinic
Manufacturing

Watson-Marlow to showcase new Bredel CIP pump and innovative fluid handling solutions at PPMA

Watson-Marlow Fluid Technology Solutions (WMFTS) will unveil the new Bredel CIP pump as well as highlight its advanced fluid management technologies during PPMA at the NEC in Birmingham, UK, from 23-25 September 2025
Manufacturing

Evonik and Ethris partner to develop novel lipid nanoparticle platform for nucleic acid delivery

The partnership will enable Evonik to bring more stable and targeted nucleic acid therapies and vaccines to market
Manufacturing

Continuous innovation: redefining the future of pharmaceutical manufacturing

In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
Manufacturing

LGC Group opens $100m Organic Chemistry Synthesis Centre of Excellence in Ontario

The new facility in Vaughn is one of the largest of its kind in the world and will ship to more than 170 countries
Subscribe now